StockData

Shoulder Innovations vs Si-Bone

SI and SIBN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SI and SIBN compare

Si-Bone is the larger company, worth 2.4 times as much as Shoulder Innovations ($1.1B against $431M).

Shoulder Innovations grew revenue faster over the last twelve months (54.9% versus 15.3% for Si-Bone).

Si-Bone keeps more of each dollar of sales as profit, with a net margin of −6.9% compared with −51.7% at Shoulder Innovations.

Si-Bone scores higher on the StockData Score (11 against 8 for Shoulder Innovations), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSISIBN
Size and price
Market cap$431M$1.1B
Share price$20.69$23.44
Change, 1 year37.9%30.2%
Change, 5 years–10.4%
Beta (5Y)–0.80
Employees75376
StockData Score
Total score811 (better)
Valuation score00
Growth score34 (better)
Performance score13 (better)
Health score44
Dividend score00
Valuation
P/S6.7×4.9× (better)
P/B3.6× (better)5.8×
FCF yield−9.9%−0.42% (better)
Fair value$13.60$16.34
Margin of safety−52.1%−43.4% (better)
Growth
Revenue growth (TTM)54.9% (better)15.3%
Revenue growth, 5Y average–22.3%
Profitability
Gross margin77.8%79.5% (better)
Operating margin−54.4%−8.3% (better)
Net margin−51.7%−6.9% (better)
FCF margin−66.2%−2.1% (better)
Return on equity−25.1%−8.3% (better)
Return on invested capital−83.6%−19.6% (better)
Financial health
Debt / equity0.13 (better)0.20
Interest coverage–−7.1×
Current ratio10.68 (better)9.15
Altman Z-score8.96 (better)8.48
Piotroski F-score46 (better)
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.8%108%
Held by insiders40.0%3.7%
Insider net buying, 12 months−$5.3M (better)−$14.6M
Short interest, % of float5.7%10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.